A novel animal model for in vivo study of liver cancer metastasis

World Journal of Gastroenterology

Volumn 18, Issue 29, 2012, Pages 3875-3882

  Fujiwara, Shinsuke ^a   Fujioka, Hikaru ^a   Tateno, Chise ^b,c   Taniguchi, Ken ^a   Ito, Masahiro ^a   Ohishi, Hiroshi ^b   Utoh, Rie ^a,c   Ishibashi, Hiromi ^a   Kanematsu, Takashi ^d   Yoshizato, Katsutoshi ^b,c,e  

^a NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^b PhoenixBio USA Corporation   (Japan)

^c Hiroshima Prefectural Univ   (Japan)

^d NAGASAKI UNIVERSITY   (Japan)

^e OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Alpha fetoprotein producing gastric cancer cells; Liver cancer metastasis; Mouse with humanized liver; Urokinase type plasminogen activator severe combined immunodeficient mouse

Indexed keywords

ALBUMIN; ALPHA FETOPROTEIN; UROKINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER SURVIVAL; CELL CULTURE; CELL TRANSPLANTATION; CHILD; CONTROLLED STUDY; ENGRAFTMENT; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; LIVER CANCER; LIVER CELL; LIVER HISTOLOGY; LIVER METASTASIS; MOUSE; NONHUMAN; PRESCHOOL CHILD; SCID MOUSE; STOMACH CANCER; TUMOR DIFFERENTIATION;

EID: 84864832632     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v18.i29.3875     Document Type: Article

References (40)

1. Yamamoto J, Saiura A, Koga R, Seki M, Ueno M, Oya M, Azekura K, Seto Y, Ohyama S, Fukunaga S, Yamaguchi T, Kokudo N, Makuuchi M, Muto T. Surgical treatment for metastatic malignancies. Nonanatomical resection of liver metastasis: indications and outcomes. Int J Clin Oncol 2005; 10: 97-102
2. Ishizu K, Sunose N, Yamazaki K, Tsuruo T, Sadahiro S, Makuuchi H, Yamori T. Development and characterization of a model of liver metastasis using human colon cancer HCT-116 cells. Biol Pharm Bull 2007; 30: 1779-1783
3. Leen E, Ceccotti P, Moug SJ, Glen P, MacQuarrie J, Angerson WJ, Albrecht T, Hohmann J, Oldenburg A, Ritz JP, Horgan PG. Potential value of contrast-enhanced intraoperative ultrasonography during partial hepatectomy for metastases: an essential investigation before resection? Ann Surg 2006; 243: 236-240
4. Giavazzi R, Campbell DE, Jessup JM, Cleary K, Fidler IJ. Metastatic behavior of tumor cells isolated from primary and metastatic human colorectal carcinomas implanted into different sites in nude mice. Cancer Res 1986; 46: 1928-1933
5. Takamura M, Sakamoto M, Genda T, Ichida T, Asakura H, Hirohashi S. Inhibition of intrahepatic metastasis of human hepatocellular carcinoma by Rho-associated protein kinase inhibitor Y-27632. Hepatology 2001; 33: 577-581
6. Niedergethmann M, Alves F, Neff JK, Heidrich B, Aramin N, Li L, Pilarsky C, Grützmann R, Allgayer H, Post S, Gretz N. Gene expression profiling of liver metastases and tumour invasion in pancreatic cancer using an orthotopic SCID mouse model. Br J Cancer 2007; 97: 1432-1440
7. Bosma GC, Custer RP, Bosma MJ. A severe combined immunodeficiency mutation in the mouse. Nature 1983; 301: 527-530
8. Suemizu H, Hasegawa M, Kawai K, Taniguchi K, Monnai M, Wakui M, Suematsu M, Ito M, Peltz G, Nakamura M. Establishment of a humanized model of liver using NOD/Shiscid IL2Rgnull mice. Biochem Biophys Res Commun 2008; 377: 248-252
9. Suemizu H, Monnai M, Ohnishi Y, Ito M, Tamaoki N, Nakamura M. Identification of a key molecular regulator of liver metastasis in human pancreatic carcinoma using a novel quantitative model of metastasis in NOD/SCID/gammacnull (NOG) mice. Int J Oncol 2007; 31: 741-751
10. Heckel JL, Sandgren EP, Degen JL, Palmiter RD, Brinster RL. Neonatal bleeding in transgenic mice expressing urokinase-type plasminogen activator. Cell 1990; 62: 447-456
11. Mercer DF, Schiller DE, Elliott JF, Douglas DN, Hao C, Rinfret A, Addison WR, Fischer KP, Churchill TA, Lakey JR, Tyrrell DL, Kneteman NM. Hepatitis C virus replication in mice with chimeric human livers. Nat Med 2001; 7: 927-933
12. Tateno C, Yoshizane Y, Saito N, Kataoka M, Utoh R, Yamasaki C, Tachibana A, Soeno Y, Asahina K, Hino H, Asahara T, Yokoi T, Furukawa T, Yoshizato K. Near completely humanized liver in mice shows human-type metabolic responses to drugs. Am J Pathol 2004; 165: 901-912
13. Utoh R, Tateno C, Yamasaki C, Hiraga N, Kataoka M, Shimada T, Chayama K, Yoshizato K. Susceptibility of chimeric mice with livers repopulated by serially subcultured human hepatocytes to hepatitis B virus. Hepatology 2008; 47: 435-446
14. Yoshizato K, Tateno C. A human hepatocyte-bearing mouse: an animal model to predict drug metabolism and effectiveness in humans. PPAR Res 2009; 2009: 476217
15. Yoshizato K, Tateno C. In vivo modeling of human liver for pharmacological study using humanized mouse. Expert Opin Drug Metab Toxicol 2009; 5: 1435-1446
16. Chang YC, Nagasue N, Abe S, Taniura H, Kumar DD, Nakamura T. Comparison between the clinicopathologic features of AFP-positive and AFP-negative gastric cancers. Am J Gastroenterol 1992; 87: 321-325
17. Sekiguchi M, Fujii Y, Saito A, Suzuki T, Shiroko Y, Nakamura H, Hasumi K. Alpha-fetoprotein-producing gastric carcinoma: biological properties of a cultured cell line. J Gastroenterol 1995; 30: 589-598
18. Kamata S, Kishimoto T, Kobayashi S, Miyazaki M, Ishikura H. Possible involvement of persistent activity of the mammalian target of rapamycin pathway in the cisplatin resistance of AFP-producing gastric cancer cells. Cancer Biol Ther 2007; 6: 1036-1043
19. Amemiya H, Kono K, Mori Y, Takahashi A, Ichihara F, Iizuka H, Sekikawa T, Matsumoto Y. High frequency of c-Met expression in gastric cancers producing alpha-fetoprotein. Oncology 2000; 59: 145-151
20. Shanmukhappa K, Matte U, Degen JL, Bezerra JA. Plasminmediated proteolysis is required for hepatocyte growth factor activation during liver repair. J Biol Chem 2009; 284: 12917-12923
21. Sandgren EP, Palmiter RD, Heckel JL, Daugherty CC, Brinster RL, Degen JL. Complete hepatic regeneration after somatic deletion of an albumin-plasminogen activator transgene. Cell 1991; 66: 245-256
22. Van Buren G, Gray MJ, Dallas NA, Xia L, Lim SJ, Fan F, Mazar AP, Ellis LM. Targeting the urokinase plasminogen activator receptor with a monoclonal antibody impairs the growth of human colorectal cancer in the liver. Cancer 2009; 115: 3360-3368
23. Madsen MA, Deryugina EI, Niessen S, Cravatt BF, Quigley JP. Activity-based protein profiling implicates urokinase activation as a key step in human fibrosarcoma intravasation. J Biol Chem 2006; 281: 15997-16005
24. Obermajer N, Doljak B, Kos J. Cytokeratin 8 ectoplasmic domain binds urokinase-type plasminogen activator to breast tumor cells and modulates their adhesion, growth and invasiveness. Mol Cancer 2009; 8: 88
25. Desdouets C, Fabre M, Gauthier F, Bréchot C, Sobczak-Thépot J. Proliferation and differentiation of a human hepatoblastoma transplanted in the Nude mouse. J Hepatol 1995; 23: 569-577
26. Leveille-Webster CR, Arias IA. Establishment and serial quantification of intrahepatic xenografts of human hepatocellular carcinoma in severe combined immunodeficiency mice, and development of therapeutic strategies to overcome multidrug resistance. Clin Cancer Res 1996; 2: 695-706
27. Miyoshi E, Noda K, Ko JH, Ekuni A, Kitada T, Uozumi N, Ikeda Y, Matsuura N, Sasaki Y, Hayashi N, Hori M, Taniguchi N. Overexpression of alpha1-6 fucosyltransferase in hepatoma cells suppresses intrahepatic metastasis after splenic injection in athymic mice. Cancer Res 1999; 59: 2237-2243
28. Kollmar O, Schilling MK, Menger MD. Experimental liver metastasis: standards for local cell implantation to study isolated tumor growth in mice. Clin Exp Metastasis 2004; 21: 453-460
29. Hardy B, Morgenstern S, Raiter A, Rodionov G, Fadaeev L, Niv Y. BAT monoclonal antibody immunotherapy of human metastatic colorectal carcinoma in mice. Cancer Lett 2005; 229: 217-222
30. Schnater JM, Bruder E, Bertschin S, Woodtli T, de Theije C, Pietsch T, Aronson DC, von Schweinitz D, Lamers WH, Köhler ES. Subcutaneous and intrahepatic growth of human hepatoblastoma in immunodeficient mice. J Hepatol 2006; 45: 377-386
31. Meuleman P, Leroux-Roels G. The human liver-uPA-SCID mouse: a model for the evaluation of antiviral compounds against HBV and HCV. Antiviral Res 2008; 80: 231-238
32. Kato R. Characteristics and differences in the hepatic mixed function oxidases of different species. Pharmacol Ther 1979; 6: 41-98
33. Green CE, LeValley SE, Tyson CA. Comparison of amphetamine metabolism using isolated hepatocytes from five species including human. J Pharmacol Exp Ther 1986; 237: 931-936
34. Naritomi Y, Terashita S, Kimura S, Suzuki A, Kagayama A, Sugiyama Y. Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans. Drug Metab Dispos 2001; 29: 1316-1324
35. Hata Y, Uchino J, Sato K, Sasaki F, Une Y, Naito H, Manabe K, Kuwahara T, Kasai Y. Establishment of an experimental model of human hepatoblastoma. Cancer 1982; 50: 97-101
36. Fuchs J, Wenderoth M, von Schweinitz D, Haindl J, Leuschner I. Comparative activity of cisplatin, ifosfamide, doxorubicin, carboplatin, and etoposide in heterotransplanted hepatoblastoma. Cancer 1998; 83: 2400-2407
37. Kneteman NM, Mercer DF. Mice with chimeric human livers: who says supermodels have to be tall? Hepatology 2005; 41: 703-706
38. Meuleman P, Libbrecht L, De Vos R, de Hemptinne B, Gevaert K, Vandekerckhove J, Roskams T, Leroux-Roels G. Morphological and biochemical characterization of a human liver in a uPA-SCID mouse chimera. Hepatology 2005; 41: 847-856
39. Katoh M, Tateno C, Yoshizato K, Yokoi T. Chimeric mice with humanized liver. Toxicology 2008; 246: 9-17
40. Tsuge M, Hiraga N, Takaishi H, Noguchi C, Oga H, Imamura M, Takahashi S, Iwao E, Fujimoto Y, Ochi H, Chayama K, Tateno C, Yoshizato K. Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis B virus. Hepatology 2005; 42: 1046-1054